[go: up one dir, main page]

AU2001257326A1 - Topical anesthetic/opioid formulations and uses thereof - Google Patents

Topical anesthetic/opioid formulations and uses thereof

Info

Publication number
AU2001257326A1
AU2001257326A1 AU2001257326A AU5732601A AU2001257326A1 AU 2001257326 A1 AU2001257326 A1 AU 2001257326A1 AU 2001257326 A AU2001257326 A AU 2001257326A AU 5732601 A AU5732601 A AU 5732601A AU 2001257326 A1 AU2001257326 A1 AU 2001257326A1
Authority
AU
Australia
Prior art keywords
topical anesthetic
opioid formulations
opioid
formulations
anesthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001257326A
Inventor
Yuri Kolesnikov
Gavril Pasternak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2001257326A1 publication Critical patent/AU2001257326A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001257326A 2000-04-28 2001-04-27 Topical anesthetic/opioid formulations and uses thereof Abandoned AU2001257326A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20043700P 2000-04-28 2000-04-28
US60/200,437 2000-04-28
PCT/US2001/013546 WO2001082914A2 (en) 2000-04-28 2001-04-27 Topical anesthetic/opioid formulations and uses thereof

Publications (1)

Publication Number Publication Date
AU2001257326A1 true AU2001257326A1 (en) 2001-11-12

Family

ID=22741721

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001257326A Abandoned AU2001257326A1 (en) 2000-04-28 2001-04-27 Topical anesthetic/opioid formulations and uses thereof

Country Status (8)

Country Link
US (2) US6825203B2 (en)
EP (1) EP1276475A2 (en)
JP (1) JP2004512260A (en)
KR (1) KR20030060771A (en)
AU (1) AU2001257326A1 (en)
CA (1) CA2407683C (en)
IL (1) IL152473A0 (en)
WO (1) WO2001082914A2 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1102589B1 (en) * 1998-07-16 2006-11-02 Memorial Sloan-Kettering Institute For Cancer Research Topical compositions comprising an opioid analgesic and an nmda antagonist
TR200103235T2 (en) 1999-03-23 2002-01-21 James Cook University Organ retention, protection and storage.
PT2266558T (en) * 2001-06-07 2017-07-21 Analgesic Neuropharmaceuticals Llc Treatment of neuropathic pain with the n-methyl-d-aspartate (nmda) receptor antagonist dextromethorphan
DE10141650C1 (en) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
GB0121980D0 (en) 2001-09-11 2001-10-31 Cathnet Science Holding As Expandable stent
JP2003081872A (en) * 2001-09-13 2003-03-19 Nippon Oruganon Kk Itch-therapeutic agent
US7294146B2 (en) 2001-12-03 2007-11-13 Xtent, Inc. Apparatus and methods for delivery of variable length stents
US7182779B2 (en) 2001-12-03 2007-02-27 Xtent, Inc. Apparatus and methods for positioning prostheses for deployment from a catheter
US7351255B2 (en) 2001-12-03 2008-04-01 Xtent, Inc. Stent delivery apparatus and method
US20030135266A1 (en) 2001-12-03 2003-07-17 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US7137993B2 (en) 2001-12-03 2006-11-21 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US7892273B2 (en) 2001-12-03 2011-02-22 Xtent, Inc. Custom length stent apparatus
US20040186551A1 (en) 2003-01-17 2004-09-23 Xtent, Inc. Multiple independent nested stent structures and methods for their preparation and deployment
US7147656B2 (en) 2001-12-03 2006-12-12 Xtent, Inc. Apparatus and methods for delivery of braided prostheses
US7309350B2 (en) 2001-12-03 2007-12-18 Xtent, Inc. Apparatus and methods for deployment of vascular prostheses
DK1534313T3 (en) 2002-07-30 2013-02-04 Omeros Corp Ophthalmological irrigation solutions and method
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2004056181A1 (en) * 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery (2)
US7241308B2 (en) 2003-06-09 2007-07-10 Xtent, Inc. Stent deployment systems and methods
US7326236B2 (en) 2003-12-23 2008-02-05 Xtent, Inc. Devices and methods for controlling and indicating the length of an interventional element
US7323006B2 (en) 2004-03-30 2008-01-29 Xtent, Inc. Rapid exchange interventional devices and methods
US20050265219A1 (en) * 2004-05-11 2005-12-01 Texas Instruments Incorporated Orthogonal frequency division multiplex (OFDM) packet detect unit, method of detecting an OFDM packet and OFDM receiver employing the same
EP1595541A1 (en) * 2004-05-12 2005-11-16 Alcasynn Pharmaceuticals Gmbh Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
US20050288766A1 (en) 2004-06-28 2005-12-29 Xtent, Inc. Devices and methods for controlling expandable prostheses during deployment
US8317859B2 (en) 2004-06-28 2012-11-27 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
CN101291683B (en) * 2004-11-24 2011-08-17 纽普罗研究有限公司 Methods and compositions for treating disease
EP1702627A1 (en) * 2005-03-18 2006-09-20 Laboratorios Del Dr. Esteve, S.A. Analgesic combination of sodium channel blockers with opioid antagonists
ATE458491T1 (en) 2005-08-26 2010-03-15 Univ Leland Stanford Junior METHOD FOR TREATING HEADACHE BY ADMINISTRATION OF OXYTOCIN
US20070093517A1 (en) * 2005-10-24 2007-04-26 Gary Newton Local anesthetic compositions
US7695733B2 (en) 2006-02-17 2010-04-13 Zasler Nathan D Application of topical anesthetics for modulation of neurogenic tremor
EP1998716A4 (en) 2006-03-20 2010-01-20 Xtent Inc Apparatus and methods for deployment of linked prosthetic segments
KR101425579B1 (en) 2006-05-29 2014-08-13 하이버네이션 테라퓨틱스 리미티드 Improved tissue retention
KR20140108346A (en) 2006-07-25 2014-09-05 하이버네이션 테라퓨틱스 리미티드 Trauma therapy
TW200815004A (en) * 2006-09-19 2008-04-01 Chi Mei Foundation Hospital Local anesthetic composition containing dextrorotatory morphinan derivative or pharmaceutically acceptable salts thereof
US20080220062A1 (en) * 2006-10-23 2008-09-11 Psivida, Inc. Sustained release of agents for localized pain management
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
US20080199510A1 (en) 2007-02-20 2008-08-21 Xtent, Inc. Thermo-mechanically controlled implants and methods of use
EP2173353B1 (en) 2007-03-02 2015-05-06 Hibernation Therapeutics, a KF LLC Composition including Adenosine and Lignocaine
US8486132B2 (en) 2007-03-22 2013-07-16 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
WO2008144675A1 (en) 2007-05-17 2008-11-27 Neopro Labs, Llc Crystalline and amorphous forms of peptide
US20090036541A1 (en) * 2007-08-02 2009-02-05 Donald David Mardis Applicator and chemical combination for better topical anesthesia
CA2705372A1 (en) 2007-11-14 2009-05-22 Kyowa Hakko Bio Co., Ltd. Preventing or ameliorating agent for skin psoriasis
US9101503B2 (en) 2008-03-06 2015-08-11 J.W. Medical Systems Ltd. Apparatus having variable strut length and methods of use
GB0808751D0 (en) * 2008-05-14 2008-06-18 Serentis Ltd Topical compositions of opioid compound for use in wound healing
US11298252B2 (en) 2008-09-25 2022-04-12 Advanced Bifurcation Systems Inc. Stent alignment during treatment of a bifurcation
US8769796B2 (en) 2008-09-25 2014-07-08 Advanced Bifurcation Systems, Inc. Selective stent crimping
US12076258B2 (en) 2008-09-25 2024-09-03 Advanced Bifurcation Systems Inc. Selective stent crimping
US12324756B2 (en) 2008-09-25 2025-06-10 Advanced Bifurcation Systems Inc. System and methods for treating a bifurcation
EP2344068B1 (en) 2008-09-25 2022-10-19 Advanced Bifurcation Systems Inc. Partially crimped stent
US8821562B2 (en) 2008-09-25 2014-09-02 Advanced Bifurcation Systems, Inc. Partially crimped stent
CA2794064A1 (en) 2010-03-24 2011-09-29 Advanced Bifurcation Systems, Inc. Methods and systems for treating a bifurcation with provisional side branch stenting
CA2794078A1 (en) 2010-03-24 2011-09-29 Advanced Bifurcation Systems, Inc. Stent alignment during treatment of a bifurcation
CN109363807B (en) 2010-03-24 2021-04-02 高级分支系统股份有限公司 System and method for treating a bifurcation
EP3777780B1 (en) 2011-02-08 2024-04-24 Advanced Bifurcation Systems Inc. System for treating a bifurcation with a fully crimped stent
CA2826760A1 (en) 2011-02-08 2012-08-16 Advanced Bifurcation Systems, Inc. Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use
EP3284459B1 (en) 2011-04-29 2021-01-06 Moberg Pharma AB Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat
BR112013028802B1 (en) 2011-05-10 2021-10-26 Itochu Chemical Frontier Corporation NON-AQUEOUS ADHESIVE DRESSING
ES3034911T3 (en) 2011-05-10 2025-08-26 Itochu Chemical Frontier Corp Non-aqueous patch
US11786455B2 (en) 2011-05-10 2023-10-17 Itochu Chemical Frontier Corporation Non-aqueous patch
TR201810942T4 (en) 2011-09-27 2018-09-21 Itochu Chemical Frontier Corp Waterless tape.
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
AU2014292827A1 (en) 2013-07-17 2016-02-04 Hibernation Therapeutics, A Kf Llc A method for organ arrest, protection and preservation and reducing tissue injury
TWI705812B (en) 2014-12-01 2020-10-01 奥默羅斯公司 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
PT3242676T (en) 2015-01-07 2023-12-06 TONIX Pharmaceuticals Holding Corp Magnesium-containing oxytocin formulations and methods of use
CN115814055A (en) 2016-04-12 2023-03-21 三叉神经股份公司 Magnesium-containing oxytocin formulations and methods of use
US11160799B2 (en) 2019-10-22 2021-11-02 Cessatech A/S Pediatric combination
CN115135317A (en) 2020-01-22 2022-09-30 西洛斯治疗有限公司 Reducing side effects of NMDA antagonists
CN114373519A (en) * 2021-12-31 2022-04-19 苏州佩德生物医药有限公司 Virtual screening method of TRPV3 inhibitor, drug lead compound and application

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446140A (en) 1981-12-10 1984-05-01 Nelson Research & Development Company Method and composition for treating mouth pain
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
DE4223004A1 (en) 1992-07-13 1994-01-20 Liedtke Pharmed Gmbh Single-dose semi-solid topical dosage form for transdermal therapy
WO1994014427A2 (en) 1992-12-23 1994-07-07 Zymogenetics, Inc. Use of skyrin and analogues for the treatment of diabetes mellitus and process for their preparation
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5635204A (en) 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
US5589480A (en) 1994-08-17 1996-12-31 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
KR960019204A (en) 1994-11-01 1996-06-17 이헌조 CD-ROM, floppy disk drive and driving method
US5866143A (en) 1995-03-24 1999-02-02 El Khoury And Stein, Ltd. Topical application of opioid drugs such as morphine for relief of itching and skin disease
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US5840731A (en) 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
US6197830B1 (en) 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
NZ334343A (en) 1996-09-30 2001-01-26 Hoechst Marion Roussel Inc NMDA (n-methyl-d-aspartate) antagonists which preferentially bind to the strychnine-insensitive glycine binding site on the NMDA receptor complex
ES2174337T3 (en) 1996-12-16 2002-11-01 Alcon Lab Inc TOPICAL USE OF KAPPA OPIOID AGONISTS FOR THE TREATMENT OF EYE PAIN.
DK1003494T3 (en) 1997-01-22 2007-07-16 Cornell Res Foundation Inc (d) -methadone, a non-opioid analgesic
US5834480A (en) 1997-06-13 1998-11-10 Elkhoury; George F. Topical application of opioids for treatment of acne and sebaceous gland disorders
EP1102589B1 (en) 1998-07-16 2006-11-02 Memorial Sloan-Kettering Institute For Cancer Research Topical compositions comprising an opioid analgesic and an nmda antagonist
JP2000169378A (en) * 1998-12-10 2000-06-20 Taisho Pharmaceut Co Ltd Composition for pharyngeal diseases
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds

Also Published As

Publication number Publication date
CA2407683C (en) 2010-04-13
US20020052319A1 (en) 2002-05-02
JP2004512260A (en) 2004-04-22
US20020004484A1 (en) 2002-01-10
US6790855B2 (en) 2004-09-14
EP1276475A2 (en) 2003-01-22
IL152473A0 (en) 2003-05-29
CA2407683A1 (en) 2001-11-08
WO2001082914A2 (en) 2001-11-08
KR20030060771A (en) 2003-07-16
US6825203B2 (en) 2004-11-30
WO2001082914A3 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
AU2001257326A1 (en) Topical anesthetic/opioid formulations and uses thereof
AU2001277754A1 (en) Proline derivatives and use thereof as drugs
AU2001264313A1 (en) Pyrazolopyridine compounds and use thereof as drugs
AUPQ969800A0 (en) Pyrazolopyridine compound and pharmaceutical use thereof
AU2002232492A1 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
AU2001287898A1 (en) Pyrazolopyridines and pyrazolopyridazines as antidiabetics
EP1073401A4 (en) Topical anesthetic formulation
AU2002223028A1 (en) Inhaler
AU5286901A (en) Topical anesthetic formulation
AU2001222986A1 (en) Dehydroascorbic acid formulations and uses thereof
AU2002214324A1 (en) Medicinal compositions
AU2001290239A1 (en) Medicinal composition
AU2002218502A1 (en) Lactam compounds and medicinal use thereof
AU2001227084A1 (en) N-arylhydrazide compounds and use thereof as drugs
AU2001229439A1 (en) Bioconjugates and uses thereof
AU1053501A (en) Polyazanaphthalene compound and medicinal use thereof
AU4876701A (en) Peptide derivatives and medicinal compositions
AU4432001A (en) Trityl-type compounds and their use
AU2001262928A1 (en) Pharmaceutical compositions and their use
AU2001275696A1 (en) Therapeutic agent
AU2001274745A1 (en) Gluthione analogues and their use as antioxidants
AU2001278963A1 (en) Muo-conopeptides and their use as local anesthetics
AU2001259564A1 (en) Pharmaceutical compositions and methods for use
AU2001277519A1 (en) Bio-probes and use thereof
AU2001252621A1 (en) Novel proetin and use thereof